从使用基因型归算的13项临床研究中,CYP2C19和CYP2D6对抗抑郁药反应的代谢活性:一个元分析
Danyang Li1,2, Oliver Pain3, Chiara Fabbri1,4
1Social, Genetic and Developmental Psychiatry Centre, King's College London, London, GB, UK.
Translational psychiatry
|July 18, 2024
概括
在CYP2C19和CYP2D6中的遗传变异会影响身体如何处理抗抑郁药. 这项研究发现CYP2C19代谢表型与抑郁症患者抗抑郁药反应之间没有显著的关联.
科学领域:
- 药物基因组学 药物基因组学
- 临床精神病学 临床精神病学
- 遗传学 是一个遗传学.
背景情况:
- 包括CYP2C19和CYP2D6在内的P450酶对抗抑郁药物代谢至关重要.
- 这些酶的遗传多态性可以影响代谢物水平,但它们对抗抑郁药物反应的影响需要进一步调查.
研究的目的:
- 研究由遗传变异衍生的CYP2C19和CYP2D6代谢表型与抗抑郁药治疗反应之间的关联.
- 分析来自不同人群的临床和遗传数据,以了解药物遗传学对抑郁症治疗结果的影响.
主要方法:
- 收集了来自13项涉及欧洲和东亚人口的研究的个人临床和遗传数据.
- 评估抗抑郁药对缓解和百分比改善的反应.
- 导入的基因型数据以确定CYP2C19和CYP2D6代谢表型 (差,中等,正常,快速+超快速).
- 研究了CYP2C19表型与治疗反应的关联,使用正常代谢器作为参考组.
主要成果:
- 总共分析了5843名抑郁症患者.
- 在 CYP2C19 低代谢者中观察到较高缓解率的趋势,但在多次测试校正后没有达到统计学意义.
- 在CYP2C19代谢表型和抑郁症症状的百分比改善之间没有发现显著的关联.
- 通过CYP2C19代谢的特定抗抑郁药物的分层也没有显示出任何显著的关联.
- 在欧洲和东亚祖先群体之间注意到了代谢表型频率的差异,但不是它们对反应的影响.
结论:
- 从CYP2C19的遗传变异推断出的代谢表型在这个大型元分析中与抗抑郁药反应没有显著的关联.
- 虽然CYP2C19低代谢者显示出更好的缓解趋势,但需要进一步研究,进行全面的药物遗传学测试,以确认潜在的疗效.
- 未来的研究应该将遗传数据与临床因素,副作用概况和各种祖先数据相结合,以便更全面地了解抗抑郁药治疗的药物遗传影响.
相关概念视频
Antidepressant Drugs: Overview
425
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
425
Antidepressant Drugs: MAOIs and Other Agents
209
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
115
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
115
Human Genetics
556
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
556
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
352
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
352
Factors Affecting Drug Biotransformation: Biological
136
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
136


